Novel Mechanisms and Interventions for PTSD
This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field. Articles from the bibliography that are reprinted in this issue are in bold type.
References
Abdallah CG, Averill LA, Akiki TJ, et al: The neurobiology and pharmacotherapy of posttraumatic stress disorder. Annu Rev Pharmacol Toxicol 2019; 59:171–189
Abdallah CG, Roache JD, Gueorguieva R, et al: Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology 2022; 47:1574–1581
Bryant RA: Acute stress disorder as a predictor of posttraumatic stress disorder: a systematic review. J Clin Psychiatry 2011; 72:233–239
Bryant RA, McFarlane AC, Silove D, et al: The lingering impact of resolved PTSD on subsequent functioning. Clin Psychol Sci 2016; 4:493–498
deRoon-Cassini TA, Hunt JC, Geier TJ, et al: Screening and treating hospitalized trauma survivors for posttraumatic stress disorder and depression. J Trauma Acute Care Surg 2019; 87:440–450
Feder A, Costi S, Rutter SB, et al: A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry 2021; 178:193–202
Feduccia AA, Jerome L, Yazar-Klosinski B, et al: Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front Psychiatry 2019; 10:650–659
Forman-Hoffman V, Middleton JC, Feltner C, et al: Psychological and Pharmacological Treatments for Adults with Posttraumatic Stress Disorder: A Systematic Review Update. Rockville, MD, Agency for Healthcare Research and Quality, 2022
Freudenmann RW, Öxler F, Bernschneider-Reif S: The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction 2006; 101:1241–1245
Garfinkel SN, Gould van Praag CD, Engels M, et al: Interoceptive cardiac signals selectively enhance fear memories. J Exp Psychol Gen 2021; 150:1165–1176
Green AR, Mechan AO, Elliott JM, et al: The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev 2003; 55:463–508
Grob CS, Poland RE, Chang L, et al: Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 1996; 73:103–107
Jovanovic T, Ressler KJ: How the neurocircuitry and genetics of fear inhibition may inform our understanding of PTSD. Am J Psychiatry 2010; 167:648–662
Kearney BE, Lanius RA: The brain-body disconnect: a somatic sensory basis for trauma-related disorders. Front Neurosci 2022; 16:1015749
Khalsa SS, Adolphs R, Cameron OG, et al: Interoception and mental health: a roadmap. Biol Psychiatry Cogn Neurosci Neuroimaging 2018; 3:501–513
Kilpatrick DG, Resnick HS, Milanak ME, et al: National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 criteria. J Trauma Stress 2013; 26:537–547
Krediet E, Bostoen T, Breeksema J, et al: Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol 2020; 23:385–400
Kuypers KP, Dolder PC, Ramaekers JG, et al: Multifaceted empathy of healthy volunteers after single doses of MDMA: a pooled sample of placebo-controlled studies. J Psychopharmacol 2017; 31:589–598
Lepow L, Morishita H, Yehuda R: Critical period plasticity as a framework for psychedelic-assisted psychotherapy. Front Neurosci 2021; 15:710004
Maddox SA, Hartmann J, Ross RA, et al: Deconstructing the gestalt: mechanisms of fear, threat, and trauma memory encoding. Neuron 2019; 102:60–74
Maren S, Phan KL, Liberzon I: The contextual brain: implications for fear conditioning, extinction and psychopathology. Nat Rev Neurosci 2013; 14:417–428
Marseille E, Kahn JG, Yazar-Klosinski B, et al: The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. PLoS One 2020; 15:e0239997
Merians AN, Spiller T, Harpaz-Rotem I, et al: Post-traumatic stress disorder. Med Clin North Am 2023; 107:85–99
Mitchell JM, Bogenschutz M, Lilienstein A, et al: MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 2021; 27:1025–1033
Mithoefer MC, Feduccia AA, Jerome L, et al: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl) 2019; 236:2735–2745
Mithoefer MC, Wagner MT, Mithoefer AT, et al: The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 2011; 25:439–452
Norbury A, Rutter SB, Collins AB, et al: Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. Neuropsychopharmacology 2021; 46:2266–2277
Ot’alora GM, Grigsby J, Poulter B, et al: 3,4-methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial. J Psychopharmacol 2018; 32:1295–1307
Price M, van Stolk-Cooke K, Brier ZMF, et al: mHealth solutions for early interventions after trauma: improvements and considerations for assessment and intervention throughout the acute post-trauma period. MHealth 2018; 4:22
Schenk S, Newcombe D: Methylenedioxymethamphetamine (MDMA) in psychiatry: pros, cons, and suggestions. J Clin Psychopharmacol 2018; 38:632–638
Thal SB, Lommen MJ: Current perspective on MDMA-assisted psychotherapy for posttraumatic stress disorder. J Contemp Psychother 2018; 48:99–108
Wagner MT, Mithoefer MC, Mithoefer AT, et al: Therapeutic effect of increased openness: investigating mechanism of action in MDMA-assisted psychotherapy. J Psychopharmacol 2017; 31:967–974
Information & Authors
Information
Published In
History
Published in print: Summer 2023
Published online: 14 July 2023
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
PDF/ePub
View PDF/ePubGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).